Zoetis (ZTS)

NYSE Health Care Pharmaceuticals S&P 500
$79.40
-2.71 (-3.30%)
Close of Nov 06, 2026 · end-of-day data

ZTS 8-K filings in 2024

Every material Form 8-K Zoetis filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 2024116 on record in all
Latest filing in 2024Nov 12, 2024leadership
High impact (4-5)0of 1 brief
ToneNeutral1
Nov 12, 6:27 AM ET

Zoetis names Jamie Brannan chief commercial officer; digital chief Mamilli to leave

Neutral leadership Written later 5.018.01

Zoetis announced on November 11, 2024 a set of executive changes. Jamie Brannan was named to a newly created Chief Commercial Officer role overseeing commercial operations in the U.S. and all international markets, and Keith Sarbaugh was promoted to Chief Digital & Technology Officer. Two executives are departing in early 2025, and the filing does not include any financial results or guidance.

  • Jamie Brannan appointed to newly created Executive Vice President and Chief Commercial Officer role, effective immediately, overseeing all commercial markets.
  • Wafaa Mamilli, Executive Vice President and Chief Digital & Technology Officer, will leave in early 2025 to pursue an external opportunity.
  • Ester Banque, Executive Vice President and President, U.S. Operations, will leave and serve in an advisory capacity until early 2025.
  • Jared Shriver promoted to President, U.S. Operations, reporting to Mr. Brannan, effective immediately.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zoetis filing is on SEC EDGAR ↗. 8-K briefs of other companies →